All In Biotech

Drug Trial Radar · NCT06686654

Study of a Human Metapneumovirus/Respiratory Syncytial Virus mRNA Vaccine Candidate Encapsulated in a Lipid Nanoparticle-based Formulation in Adults Aged 60 Years and Older

A Phase 1/2, Randomized, Observer-blind, Placebo-controlled Multi-arm Study to Evaluate the Safety and Immunogenicity of an hMPV/RSV mRNA Vaccine Candidate in Adult Participants Aged 60 Years and Older

Last checked: Nov 20, 2026Latest source record: Dec 11, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingRandomized with 1,530 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

1,530

Actual

Start

Nov 11, 2024

Primary completion

Jan 18, 2027

Study completion Jan 18, 2027

Sponsor

Lead sponsor
Sanofi Pasteur, a Sanofi CompanySanofi (SNY)
Sponsor type
Industry
First posted
Nov 13, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Prevention
FDA-regulated drug
Yes
Who can join
All sexes, from 60 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The aim of this study is to evaluate the safety and immunogenicity of a human metapneumovirus (hMPV) / respiratory syncytial virus (RSV) mRNA vaccine candidate encapsulated in a lipid nanoparticle (LNP) based formulation (hereafter referred to as hMPV/RSV vaccine) for the prevention of lower respiratory tract disease (LRTD) caused by hMPV and/or RSV among adults aged 60 years and older. The study will also evaluate the safety and immunogenicity of a booster vaccination using a bivalent hMPV/RSV mRNA vaccine candidate (hereafter referred to as RSV+hMPV mRNA vaccine candidate). Overall, the study is designed to address the following goals: * Assess the safety profile of the candidate formulations. * Describe the immunogenicity profile of the candidate formulations. * Select the vaccine formulations (dose) for future development. * Assess the safety and immunogenicity of a booster vaccination with the RSV + hMPV mRNA vaccine candidate administered 12 months after primary vaccination with a licensed RSV vaccine. The study duration is as follows: -Six months each for the Sentinel and Main Cohorts; up to 12 months for the Expansion Cohort, and 6 additional months for the Booster Cohort Treatment duration: * Stage 1 Sentinel Cohort: 1 intra-muscular (IM) injection. Participants will be followed for 6 months post vaccination * Stage 1 Main Cohort: 1 IM injection. Participants will be followed for 6 months post vaccination * Stage 2 Expansion Cohort: 1 IM injection. Participants in the licensed RSV vaccine arm will be followed for 12 months post-vaccination; the remainder of the participants will be followed up to 8 months post-vaccination * Stage 2 Booster Cohort: 1 IM injection 12 months post-primary vaccination. Participants will be followed for 6 months post-booster vaccination

Conditions

  • Human Metapneumovirus Immunization
  • Respiratory Syncytial Virus Immunization

Interventions

  • Investigational hMPV/RSV vaccineBiological

    Investigational hMPV/RSV vaccine administered intramuscularly

  • Investigational hMPV vaccine (monovalent)Biological

    Investigational hMPV vaccine (monovalent) administered intramuscularly

  • Investigational RSV vaccine (monovalent)Biological

    Investigational RSV vaccine (monovalent) administered intramuscularly

  • Licensed RSV VaccineBiological

    Licensed RSV vaccine administered intramuscularly

  • PlaceboBiological

    Placebo administered intramuscularly

  • Investigational RSV+hMPV vaccineBiological

    Investigational RSV+hMPV vaccine administered intramuscularly

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Presence of unsolicited immediate systemic adverse events (AEs) (Stage 1 and Stage 2 Expansion and Booster Cohorts)Time frame: Within 30 minutes after primary and booster vaccinations
  2. Presence of solicited injection site and systemic reactions (Stage 1 and Stage 2 Expansion and Booster Cohorts)Time frame: Up to 7 days after primary and booster vaccinations
  3. Presence of unsolicited AEs (Stage 1 and Stage 2 Expansion and Booster Cohorts)Time frame: Up to 28 days after primary and booster vaccinations
  4. Presence of medically attended AEs (MAAEs) (Stage 1 and Stage 2 Expansion and Booster Cohorts)Time frame: Up to 6 months after primary and booster vaccinations
  5. Presence of serious AEs (SAEs) and AEs of special interest (AESIs) (Stage 1 and Stage 2 Expansion and Booster Cohorts)Time frame: Up to 6 months after primary and booster vaccinations
  6. Presence of related SAEs, related AESIs, and fatal SAEs (regardless of causality) (Stage 1 and Stage 2 Expansion and Booster Cohorts)Time frame: Throughout the duration of the study (up to approximately 24 months)
  7. Presence of out-of-range biological test results (Stage 1)Time frame: Up to 7 days after primary vaccination
  8. Presence of out-of-range biological test results (Stage 2 Booster Cohort)Time frame: Up to 7 days after booster vaccination
  9. hMPV A serum neutralizing antibodies (nAb) titers in Stage 1 Sentinel and Main CohortsTime frame: At pre-vaccination (Day 01) and 28 days post-primary vaccination (Day 29)
  10. hMPV B serum neutralizing antibodies (nAb) titers in Stage 1 Sentinel and Main CohortsTime frame: At pre-vaccination (Day 01) and 28 days post-primary vaccination (Day 29)
  11. RSV A serum nAb titers in Stage 1 Sentinel and Main CohortsTime frame: At pre vaccination (D01) and 28 days post-primary vaccination (D29)
  12. RSV B serum nAb titers in Stage 1 Sentinel and Main CohortsTime frame: At pre vaccination (D01) and 28 days post-primary vaccination (D29)
  13. hMPV A serum neutralizing antibodies (nAb) titers in Stage 2 Expansion ChortTime frame: At (Day 01) pre-vaccination and 28 days after the injection of the hMPV/RSV vaccine candidate (Day 29)
  14. hMPV B serum neutralizing antibodies (nAb) titers in Stage 2 Expansion ChortTime frame: At (Day 01) pre-vaccination and 28 days after the injection of the hMPV/RSV vaccine candidate (Day 29)
  15. RSV A serum neutralizing antibodies (nAb) titers in Stage 2 Expansion ChortTime frame: At (Day 01) pre-vaccination and 28 days after the injection of the hMPV/RSV vaccine candidate (Day 29)
  16. RSV B serum neutralizing antibodies (nAb) titers in Stage 2 Expansion ChortTime frame: At (Day 01) pre-vaccination and 28 days after the injection of the hMPV/RSV vaccine candidate (Day 29)
  17. hMPV A serum neutralizing antibodies (nAb) titers in Stage 2 Expansion ChortTime frame: At (Day 01) pre-vaccination and 28 days after the injection of the hMPV standalone vaccine (Day 29)
  18. hMPV B serum neutralizing antibodies (nAb) titers in Stage 2 Expansion ChortTime frame: At (Day 01) pre-vaccination and 28 days after the injection of the hMPV standalone vaccine (Day 29)
  19. RSV A serum neutralizing antibodies (nAb) titers in Stage 2 Expansion ChortTime frame: At (Day 01) pre-vaccination and 28 days after the injection of the RSV standalone vaccine (Day 29)
  20. RSV B serum neutralizing antibodies (nAb) titers in Stage 2 Expansion ChortTime frame: At (Day 01) pre-vaccination and 28 days after the injection of the RSV standalone vaccine (Day 29)

Locations

24 sites in 1 country. Site status is shown where the registry gives one.

  • Velocity Clinical Research, Phoenix- Site Number : 8400025

    Phoenix, Arizona

  • CenExel CNS-Garden Grove- Site Number : 8400017

    Garden Grove, California

  • National Research Institute - Gardena- Site Number : 8400005

    Gardena, California

  • National Research Institute - Huntington Park- Site Number : 8400014

    Huntington Park, California

  • Velocity Clinical Research - San Diego- Site Number : 8400008

    La Mesa, California

  • Velocity Clinical Research Los Angeles- Site Number : 8400013

    Los Angeles, California

  • National Research Institute - Panorama City- Site Number : 8400012

    Los Angeles, California

  • Providence Clinical Research - North Hollywood- Site Number : 8400018

    North Hollywood, California

  • Peninsula Research Associates- Site Number : 8400002

    Rolling Hills Estates, California

  • Velocity Clinical Research - Denver- Site Number : 8400016

    Englewood, Colorado

  • Velocity Clinical Research - Washington DC- Site Number : 8400007

    Washington D.C., District of Columbia

  • Velocity Clinical Research - Hallandale Beach- Site Number : 8400022

    Hallandale, Florida

  • Suncoast Research Associates - Miami - Sunset Drive- Site Number : 8400001

    Miami, Florida

  • Velocity Clinical Research - Meridian- Site Number : 8400003

    Meridian, Idaho

  • Velocity Clinical Research - Kansas City- Site Number : 8400015

    Overland Park, Kansas

  • Velocity Clinical Research - Rockville- Site Number : 8400011

    Rockville, Maryland

  • Velocity Clinical Research - Lincoln - Valley Road- Site Number : 8400023

    Lincoln, Nebraska

  • Velocity Clinical Research - Omaha- Site Number : 8400006

    Omaha, Nebraska

  • Velocity Clinical Research - Springdale- Site Number : 8400004

    Cincinnati, Ohio

  • Velocity Clinical Research - Medford- Site Number : 8400024

    Medford, Oregon

  • Velocity Clinical Research - Austin- Site Number : 8400020

    Cedar Park, Texas

  • Velocity Clinical Research - Salt Lake City- Site Number : 8400010

    West Jordan, Utah

  • Velocity Clinical Research - Hampton- Site Number : 8400026

    Hampton, Virginia

  • Velocity Clinical Research - Seattle- Site Number : 8400019

    Seattle, Washington

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.